Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

(2020) Josep Garcia et al.   CANCER TREATMENT REVIEWS

Efficacy & Safety of Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Non-small Cell Lung Cancer(MAPLE):A Randomized,Double-blind,Phase 3 Study

(2019) Nicholas Thatcher et al.   CLINICAL CANCER RESEARCH

Real-world treatment patterns among patients with unresected stage III non-small-cell lung cancer

(2019) Kellie J Ryan et al.   Future Oncology

Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar

(2019) Michael Thomas et al.   Immunotherapy

The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy

(2019) Eva Rahman Kabir et al.   Biomolecules

American Society of Clinical Oncology Statement: Biosimilars in Oncology

(2018) Gary H. Lyman et al.   JOURNAL OF CLINICAL ONCOLOGY

Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab

(2018) Neungseon Seo et al.   mAbs

Biosimilars in Oncology in the United States

(2018) Chadi Nabhan et al.   JAMA Oncology

Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA

(2017) Jasmina I. Ivanova et al.   MEDICAL ONCOLOGY

Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians

(2016) Hillel Cohen et al.   ADVANCES IN THERAPY

Biosimilars: Extrapolation for oncology

(2016) Giuseppe Curigliano et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Regulatory and clinical considerations for biosimilar oncology drugs

(2014) Charles L Bennett et al.   LANCET ONCOLOGY

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

(2012) Jaafar Bennouna et al.   LANCET ONCOLOGY